Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.
A study finds bradykinin modestly contributes to blood pressure reduction with sacubitril/valsartan in chronic heart failure, highlighting ANP’s role in initial effects and bradykinin’s influence during chronic therapy.
The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio
The SARAH trial demonstrates that sacubitril-valsartan significantly reduces subclinical left ventricular dysfunction in patients with elevated troponin during anthracycline chemotherapy, potentially offering a new cardioprotective strategy
The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial st
The PARAGLIDE-HF trial demonstrates that sacubitril/valsartan significantly reduces NT-proBNP in patients with LVEF >40% and worsening heart failure, regardless of left ventricular hypertrophy or left atrial enlargement, but patients wit